Söndag 22 December | 07:21:25 Europe / Stockholm

Kalender

Tid*
2025-03-06 N/A Kvartalsrapport 2025-Q2
2024-11-11 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2024-11-08 - Årsstämma
2024-09-20 - Bokslutskommuniké 2024
2024-03-07 - Kvartalsrapport 2024-Q2
2023-11-17 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2023-11-16 - Årsstämma
2023-09-28 - Bokslutskommuniké 2023
2023-04-24 - Extra Bolagsstämma 2023
2023-03-23 - Kvartalsrapport 2023-Q2
2022-11-17 - Årsstämma
2022-10-25 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2022-09-29 - Bokslutskommuniké 2022
2022-06-29 - Extra Bolagsstämma 2022
2022-02-24 - Kvartalsrapport 2022-Q2
2021-10-29 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2021-10-28 - Årsstämma
2021-09-15 - Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Nightingale Health är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.
2021-05-04 08:30:00

Company Release

4 May 2021 at 9:30 a.m. (Finnish time)

Nightingale Health Oyj restructures its Management Team and announces a strategic partnership with Reaktor to accelerate the implementation of its global expansion plan. The company's Chief R&D Officer Dr. Salla Ruosaari has been appointed to lead the company's product organization, and the company's Chief Product Officer Osma Ahvenlampi will be leaving the company to pursue other career opportunities.

In her role, Ruosaari is responsible for developing services based on the company's Health Data Platform and delivering such services to customers using superior digital solutions. With this change, Nightingale's key assets will be even more integrated to rapidly build products and create value for Nightingale's partners and consumer customers. The company's product organization will be further strengthened by the strategic partnership with Reaktor.

After the changes, members of the Management Team are CEO Teemu Suna, Chief Operation Officer Satu Saksman, Chief Technology Officer Antti Kangas, Chief R&D Officer Salla Ruosaari, Chief Legal Officer Minja Salmio and interim Chief Financial Officer Laura Pulkkinen. The changes are effective immediately.

For further information, please contact:

Teemu Suna, CEO

ir@nightingalehealth.com

Certified Adviser:

Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale

Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. By combining our pioneering blood-testing technology and the ability to detect future disease risks, we are creating a world-leading health data platform that enables preventative care with better information. The platform helps people make better personal health decisions and connects the health industry to offer their services for individuals' preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone.